Company intelligence / Profile preview
ttprizm
High Point, North Carolina, United Statesttprizm.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
TTPrizm is a biotechnology company focused on developing oral small molecule therapies for metabolic diseases, including type 2 diabetes and obesity. The company leverages its expertise in G protein-coupled receptor (GPCR) medicinal chemistry to create non-peptide, orally bioavailable agonists. Its lead programs target the GLP-1, GIP, and glucagon receptors, aiming to provide more convenient alternatives to current injectable peptide therapies. TTPrizm was formed as a spin-off or successor entity related to the metabolic disease assets of vTv Therapeutics.
- Therapeutic areas
- EndocrinologyMetabolic Disorders
- Modalities
- Small molecule
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on ttprizm.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ttprizm.